Navigation Links
The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
Date:5/5/2008

New Partnership under LLS's Therapy Acceleration Program to Advance Development of a Novel Targeted Therapy for T-Cell Leukemia and Lymphoma

WHITE PLAINS, N.Y. and VALENCIA, Calif., May 5 /PRNewswire-FirstCall/ -- The Leukemia & Lymphoma Society (LLS) and MannKind Corporation, (MNKD), today jointly announced the execution of a collaborative research arrangement funded through LLS's Therapy Acceleration Program (TAP).

TAP is an innovative program intended to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers. The TAP funding will support MannKind's efforts to develop a novel and highly selective first-in-class targeted tyrosine kinase inhibitor for the treatment of T-cell leukemia and lymphoma. This early development work, if successful, will lead to the initiation of IND-enabling studies.

"The sponsorship of LLS will help MannKind to advance its development of a potential new blood cancer treatment," said Alfred Mann, Chairman and Chief Executive Officer of MannKind. "I am personally committed to taking innovative approaches to develop effective treatments for unmet medical needs. It is exciting and gratifying to be able to collaborate with a high-caliber organization that recognizes the importance of our research."

Louis J. DeGennaro, PhD, Chief Scientific Officer of LLS, added "Our partnership with MannKind is another example of LLS's commitment to support a select group of highly motivated, well positioned commercial organizations poised to bring effective therapies to blood cancer patients."

About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its pipeline includes Technosphere(R) Insulin, which is currently in phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind is also conducting clinical trials of two investigational immunotherapy products in order to evaluate their safety and efficacy in the treatment of different types of cancer. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 66 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $486 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 4.2 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Study finds heart failure is rare among leukemia patients on imatinib
3. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Novel strategy under study for aggressive leukemia
7. Drug has ability to cure type of leukemia
8. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
9. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
Breaking Medicine Technology: